We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

maandag 27 februari 2017

Blood Cancer Journal - Table of Contents alert Volume 7 February 2017

If you are unable to see the message below, click here to view.
Blood Cancer Journal

Advertisement
Blood Cancer Journal is an online-only, open access journal, publishing high quality research on hematologic malignancies and related disorders.

Explore the benefits of submitting your next research article.

TABLE OF CONTENTS

Volume 7, February 2017

In this issue
Reviews
Original Articles
Letters to the Editor
Sign up for e-alerts Sign up for e-alerts
Web feed

Reviews

Top

Acute myeloid leukemia targets for bispecific antibodies

S S Hoseini and N K Cheung

Blood Cancer J 2017 7: e522; 10.1038/bcj.2017.2

Abstract | Full Text

The role of the extracellular matrix in primary myelofibrosis

O Leiva, S K Ng, S Chitalia, A Balduini, S Matsuura and K Ravid

Blood Cancer J 2017 7: e525; 10.1038/bcj.2017.6

Abstract | Full Text

Germline mutations predisposing to diffuse large B-cell lymphoma

O C Leeksma, N F de Miranda and H Veelken

Blood Cancer J 2017 7: e532; 10.1038/bcj.2017.15

Abstract | Full Text

Original Articles

Top

A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens

I Baccelli, J Krosl, G Boucher, I Boivin, V-P Lavallée, J Hébert, S Lemieux, A Marinier and G Sauvageau

Blood Cancer J 2017 7: e529; 10.1038/bcj.2017.10

Abstract | Full Text

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

S S Chavan, J He, R Tytarenko, S Deshpande, P Patel, M Bailey, C K Stein, O Stephens, N Weinhold, N Petty, D Steward, L Rasche, M Bauer, C Ashby, E Peterson, S Ali, J Ross, V A Miller, P Stephens, S Thanendrarajan, C Schinke, M Zangari, F van Rhee, B Barlogie, T I Mughal, F E Davies, G J Morgan and B A Walker

Blood Cancer J 2017 7: e535; 10.1038/bcj.2017.12

Abstract | Full Text

The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells

Y Nishida, A Maeda, M J Kim, L Cao, Y Kubota, J Ishizawa, A AlRawi, Y Kato, A Iwama, M Fujisawa, K Matsue, M Weetall, M Dumble, M Andreeff, T W Davis, A Branstrom, S Kimura and K Kojima

Blood Cancer J 2017 7: e527; 10.1038/bcj.2017.8

Abstract | Full Text

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies

E C Pietsch, J Dong, R Cardoso, X Zhang, D Chin, R Hawkins, T Dinh, M Zhou, B Strake, P-H Feng, M Rocca, C Dos Santos, X Shan, G Danet-Desnoyers, F Shi, E Kaiser, H J Millar, S Fenton, R Swanson, J A Nemeth and R M Attar

Blood Cancer J 2017 7: e536; 10.1038/bcj.2017.7

Abstract | Full Text

Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia

P Richter-Pechańska, J B Kunz, J Hof, M Zimmermann, T Rausch, O R Bandapalli, E Orlova, G Scapinello, J C Sagi, M Stanulla, M Schrappe, G Cario, R Kirschner-Schwabe, C Eckert, V Benes, J O Korbel, M U Muckenthaler and A E Kulozik

Blood Cancer J 2017 7: e523; 10.1038/bcj.2017.3

Abstract | Full Text

Mutational landscape reflects the biological continuum of plasma cell dyscrasias

A Rossi, M Voigtlaender, S Janjetovic, B Thiele, M Alawi, M März, A Brandt, T Hansen, J Radloff, G Schön, U Hegenbart, S Schönland, C Langer, C Bokemeyer and M Binder

Blood Cancer J 2017 7: e537; 10.1038/bcj.2017.19

Abstract | Full Text

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

N Tandon, S V Rajkumar, B LaPlant, A Pettinger, M Q Lacy, A Dispenzieri, F K Buadi, M A Gertz, S R Hayman, N Leung, R S Go, D Dingli, P Kapoor, Y Lin, Y L Hwa, A L Fonder, M A Hobbs, S R Zeldenrust, J A Lust, W I Gonsalves, S J Russell and S K Kumar

Blood Cancer J 2017 7: e528; 10.1038/bcj.2017.13

Abstract | Full Text

Letters to the Editor

Top

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia

Z Chen, L J Medeiros, H M Kantajian, L Zheng, Z Gong, K P Patel, H Xiong, W Wang, J E Cortes and S Hu

Blood Cancer J 2017 7: e521; 10.1038/bcj.2017.4

Full Text

Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma

N Lee, S Y Moon, J-h Lee, H-K Park, S-Y Kong, S-M Bang, J H Lee, S-S Yoon and D S Lee

Blood Cancer J 2017 7: e530; 10.1038/bcj.2017.14

Full Text

Splenectomy as a diagnostic method in lymphoma-associated hemophagocytic lymphohistiocytosis of unknown origin

J Ma, Z Jiang, T Ding, H Xu, J Song, J Zhang, Y Xie and W Wang

Blood Cancer J 2017 7: e534; 10.1038/bcj.2016.125

Full Text

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

M Montillo, S O'Brien, A Tedeschi, J C Byrd, C Dearden, D Gill, J R Brown, J C Barrientos, S P Mulligan, R R Furman, F Cymbalista, C Plascencia, S Chang, E Hsu, D F James and P Hillmen

Blood Cancer J 2017 7: e524; 10.1038/bcj.2017.5

Full Text

Validation of a vitamin D replacement strategy in vitamin D-insufficient patients with lymphoma or chronic lymphocytic leukemia

J G Sfeir, M T Drake, B R LaPlant, M J Maurer, B K Link, T J Berndt, T D Shanafelt, J R Cerhan, T M Habermann, A L Feldman and T Witzig

Blood Cancer J 2017 7: e526; 10.1038/bcj.2017.9

Full Text

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes

R T Swords, J Watts, H P Erba, J K Altman, M Maris, F Anwer, Z Hua, H Stein, H Faessel, F Sedarati, B J Dezube, F J Giles, B C Medeiros and D J DeAngelo

Blood Cancer J 2017 7: e520; 10.1038/bcj.2017.1

Full Text

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group